Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069154 | 0.85 | THRB (0.56) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4009260 | 0.84 | RAB9A (0.44) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL13179141 | 0.83 | HDAC6 (0.43) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27295981 | 0.82 | RAB9A (0.66) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17483168 | 0.82 | RAB9A (0.49) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4009973 | 0.80 | SMN1; SMN2 (0.48) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17483090 | 0.79 | RAB9A (0.47) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2328124 | 0.79 | NOTUM (0.43) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17483109 | 0.78 | RAB9A (0.74) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17483066 | 0.78 | RAB9A (0.47) | RAB9AHPGDSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430006-B1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8889702-B2 | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-11-18 | — | — | US | disclosed |
| EP-2430012-B1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| EP-2356108-B1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| EP-2393809-B1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8697883-B2 | Cyclopenta[C]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20130211087-A1 | 7-AZA-SPIRO[3,5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-08-15 | — | — | US | disclosed |
| US-8394787-B2 | 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20120129830-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2430006-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430012-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-21 | — | — | EP | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
| EP-2393809-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-2356108-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010130944-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130945-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010089510-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211087-A1 | 7-AZA-SPIRO[3,5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FAAH, FAAH2, ASAH1 | RAB9A 1397/4885HPGD 145/4885SMN1; SMN2 4141/4885 |
| US-20120129830-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | HDAC7, NR3C2, EPOR | RAB9A 328/4885HPGD 2137/4885SMN1; SMN2 1715/4885 |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | RAB9A 331/4885HPGD 2068/4885SMN1; SMN2 3115/4885 |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | RAB9A 302/4885HPGD 2223/4885SMN1; SMN2 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.